Wednesday, July 8, 2026

pharma · Duchenne Muscular Dystrophy · Muscular Dystrophies · CAPR

CAPRICOR THERAPEUTICS

CAPRICOR THERAPEUTICS is a pharma organization headquartered in San Diego, USA. It trades on NYSE under ticker CAPR. Primary therapeutic focus areas include Duchenne Muscular Dystrophy, Muscular Dystrophies, Covid19, Dil

San Diego, USA HQ
2005 Founded
240 Employees
Public company Type
CAPR · NYSE Ticker
Company details
Status
Public
HQ
San Diego, USA
Founded
2005
Employees
240
Programs
8
Drugs
6
Patents
43
Clinical program

Allogeneic Cardiosphere-Derived Cells (CAP-1002)

Phase 2 · small molecule · Duchenne Muscular Dystrophy

Allogeneic Cardiosphere-Derived Cells (CAP-1002) for Duchenne Muscular Dystrophy is a Phase 2 program (small_molecule) at CAPRICOR THERAPEUTICS, INC. with 2 ClinicalTrials.gov record(s).

← All CAPRICOR THERAPEUTICS, INC. projects Phase 2 small molecule completed

Internal code CAP-1002-DMD-01

Full intelligence profile for this program is being prepared.

At a glance

Sponsor
CAPRICOR THERAPEUTICS, INC.
Phase
Phase 2
Modality
small_molecule
Indication
Duchenne Muscular Dystrophy
Status
completed
Trials
2